Search

for
Search:

Sort by

Research

810-840 / 1000+ results

Diphencyprone and Topical Tacrolimus as Two Topical Immunotherapeutic Modalities: Are They Effective in the Treatment of Alopecia Areata Among Egyptian Patients? A Study Using CD4, CD8, and MHC II as Markers

research Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers

13 citations , June 2010 in “Journal of dermatological treatment”

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

research 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo

July 2022 in “Journal of Investigative Dermatology”

research A Mouse Model for the Basal Transcription/DNA Repair Syndrome Trichothiodystrophy

188 citations , June 1998 in “Molecular cell”

Researchers created a mouse with the same mutation as humans with trichothiodystrophy, showing similar symptoms and confirming the condition is due to defects in DNA repair and gene activity.

research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

3 citations , November 2024 in “Clinical Research”

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

research Tebentafusp-tebn (Kimmtra®)

March 2022 in “Oncology Times”

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

research Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis

47 citations , September 1995 in “British Journal of Dermatology”

Diphencyprone therapy for hair loss can cause vitiligo.

research All-trans-retinoic acid inhibits mink hair follicle growth via inhibiting proliferation and inducing apoptosis of dermal papilla cells through TGF-β2/Smad2/3 pathway

10 citations , August 2020 in “Acta histochemica”

All-trans-retinoic acid stops mink hair growth by affecting cell growth and causing cell death.

research Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata

13 citations , September 2022 in “Frontiers in immunology”

Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.

research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.

May 2019 in “Journal of clinical oncology”

Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.

research Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport

December 2023 in “Journal of ethnopharmacology”

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

4 citations , October 2018 in “Asia-Pacific Journal of Clinical Oncology”

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

research α‐Difluoromethylornithine, a polyamine inhibitor: its potential role in controlling hair growth and in cancer treatment and chemo‐prevention

9 citations , April 2006 in “International Journal of Dermatology”

DFMO may help control hair growth and treat cancer.

research Fluorouracil-Induced Reactive Follicular Squamous Cell Carcinoma

1 citations , July 2016 in “Dermatologic surgery”

Experimental Assessment of 3-Meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-Alpha-Reductase Inhibitors in Silico and in Vivo Models

research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models

January 2023 in “Bioorganičeskaâ himiâ”

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

research In vivo microautoradiography of [3H]1,24(OH)2D3 (tacalcitol) following topical application to normal rats and in vitro metabolism in human keratinocytes

7 citations , April 1996 in “Archives of dermatological research”

Topical tacalcitol can treat psoriasis by acting directly on skin cells.

research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair

October 2023

research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease

33 citations , January 2018 in “Blood”

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS

April 2017 in “Leukemia research”

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

research Abstract 5357: Targeting mTORC1 suppresses proliferation of keratinocyte stem cells and inhibits skin tumor promotion in mice

October 2014 in “Cancer research”

Blocking mTORC1 reduces skin tumor growth in mice.

Discovery of (2S)-N-(6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)-3-(6-(4-Cyanophenyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)-2-Hydroxy-2-Methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment

research Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment

December 2023 in “Journal of Medicinal Chemistry”

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata

research A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.

August 2025 in “PubMed”

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Possible Advantage of Imiquimod and Diphenylcyclopropenone Combined Treatment Versus Diphenylcyclopropenone Alone: An Observational Study of Nonresponder Patients With Alopecia Areata

research Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata

9 citations , April 2016 in “Australasian journal of dermatology”

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.